Promotion of fat loss : GLP-1 therapy specifically targets fat loss rather than muscle mass, which helps improve body composition during weight loss
The evidence base is still limited, however, and GLP-1 drugs are not currently approved as treatments for male infertility
The largest trial of ERAs, SONAR, including 2648 participants with type 2 diabetes and proteinuric CKD, demonstrated that atrasentan on top of RAS inhibition significantly lowered the risk of a doubling of serum creatinine or ESKD compared with placebo by 35% [75]
If you have experienced skin reactions with copper peptide serums, see Copper Peptides Ruined My Skin and Copper Peptide Irritation Guide for troubleshooting
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
The once-weekly dosing and gradual dose escalation protocol may help minimise side effects